CJC-1295 is two different molecules sold under one name, and only one of them has human dosing on record. The long-acting form (with DAC) was given under the skin in micrograms per kilogram of body weight in two small trials and one terminated Phase 2 study. The short form most people actually inject (no DAC, also called Mod GRF 1-29) has no published human study at all. Everything people quote for it, and for the very popular pairing with ipamorelin, comes from wikis, clinics and forums. This guide tables every figure, tags it by source quality and keeps the two forms apart. The pairing has a companion page: ipamorelin dosage.
Ask PeptideBlog about any peptide
Quick answer: CJC-1295 has no approved dose. Published human work used only the long-acting DAC form, injected under the skin: 30 or 60 mcg/kg were the best-tolerated levels in healthy adults, and a later study gave 60 or 90 mcg/kg once.[2][3] The no-DAC form has no human study. Online protocols report 1 to 2 mg a week for DAC and 100 to 200 mcg two or three times a day for no-DAC, and I could not trace either figure to a trial.[18][30] Background is on the with DAC entry and the no DAC entry.
Figures on this page summarize amounts and schedules reported in published research, regulator documents or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Papers write micrograms as µg. This page writes mcg, the same unit, and 1 mg is 1,000 mcg. Trials dose in mcg/kg, online protocols in flat mcg or mg. The units guide covers mg, mcg and syringe units.

Every studied or reported CJC-1295 amount at a glance
The first rows are published human trials, all of the DAC form. Registered, animal and non-label rows follow, each tagged with the quality of its source. There is no label row because no approved CJC-1295 product exists. Read the “Form” column first: DAC and no-DAC amounts are not interchangeable.
Swipe the table sideways to see every column.
| Source | Form | Population | Route | Amount | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|---|---|
| Ascending-dose trials (Teichman 2006) | DAC | Healthy adults aged 21 to 61 | Subcutaneous | Four ascending single doses, amounts not stated in the abstract; best tolerated at 30 or 60 mcg/kg | Single dose, or 2 to 3 doses weekly or every 2 weeks | Two trials of 28 and 49 days | Published human clinical trial (Tier 1)[2] |
| Pulsatility study (Ionescu and Frohman 2006) | DAC | Healthy men aged 20 to 40 | Injection; route not stated in the abstract | 60 or 90 mcg/kg | Single dose | Sampling 1 week later | Published human clinical trial (Tier 1)[3] |
| Serum protein study (Sackmann-Sala 2009) | DAC | 11 healthy young men | Injection | Not stated in the abstract | Single dose | Samples 1 week later | Published human study (Tier 1); dose unknown[4] |
| Phase 2, HIV visceral obesity (NCT00267527) | DAC | HIV patients; 120 enrolled in the registry, 192 per a news report | Not stated in the sources | Low arm 60, 90 then 120 mcg/kg; high arm 60, 120 then 240 mcg/kg | Once weekly, escalating over 3 weeks | 12 weeks planned; stopped in July 2006 | Registered human trial, terminated, no results; amounts from trade press (Tier 2)[6][7] |
| Any human study | No DAC | None found | Not applicable | No established or reliably sourced dosing information was identified | Not applicable | Not applicable | No published human study; a 2026 review rates it “no peer-reviewed human studies”[18] |
| Knockout mouse growth study (Alba 2006) | DAC | GHRH-knockout mice | Subcutaneous | 2 mcg per mouse | Every 24, 48 or 72 hours | 5 weeks | Published animal research (Tier 3)[5] |
| Narrative review of online self-administration (2026) | DAC | People described in bodybuilding forums | Subcutaneous | 1 to 2 mg per week | 1 to 2 injections a week | 8 to 12 or 12 to 16 weeks on, 4 to 6 weeks off | Practitioner reported (Tier 5), summarizing community reports[18] |
| Same review | No DAC | People described in forums | Subcutaneous | 100 to 200 mcg per injection | 1 to 2 times a day, often with ipamorelin | 12 to 16 weeks on, 4 to 6 weeks off | Practitioner reported (Tier 5), summarizing community reports[18] |
| Wiki community page, 4 protocols from “130 community reports” | DAC | Not applicable | Subcutaneous | 2 mg; 1 mg; 300 to 1,000 mcg rising; 1 mg | Once weekly; twice weekly; twice weekly; once weekly | 12 to 16 weeks; ongoing with breaks | Community, vendor or clinic reported (Tier 6)[29] |
| Wiki dosing page | No DAC | Not applicable | Subcutaneous | 100 mcg per injection, range 100 to 200 mcg | 2 to 3 times daily | 8 to 12 weeks, repeatable | Community, vendor or clinic reported (Tier 6); page says no dose-finding study exists[30] |
| Wiki community page, 4 protocols from “180 community reports” | No DAC | Not applicable | Subcutaneous | 100 mcg with 100 mcg ipamorelin; 100 to 200 mcg; 200 mcg with 200 mcg ipamorelin; 100 to 200 mcg | 2 to 3 times daily; 1 to 3 times daily; once before bed; after workouts 3 to 5 days a week | 8 to 16 weeks; 8 to 12 weeks; 12 or more weeks; 8 to 12 weeks | Community, vendor or clinic reported (Tier 6)[31] |
| Comparison page on a peptide database site | Both | Not applicable | Not stated | No DAC 100 to 300 mcg; DAC 1 to 2 mg | No DAC 2 to 3 times daily; DAC once or twice weekly | Not stated | Community, vendor or clinic reported (Tier 6); lists no citations[34] |
| Physician-authored guide on a site tied to a telehealth practice | Both | Not applicable | Subcutaneous | DAC about 2 mg; no DAC 100 to 200 mcg, each with ipamorelin | DAC weekly; no DAC nightly | 8 to 12 weeks, 4 week break; up to 6 months suggested by some providers | Practitioner reported (Tier 5); dosing figures carry no citation[35] |
| Website figures recorded in FDA’s briefing | Not specified | Not applicable | Not stated | 100 mcg per week; 100 to 400 mcg per day; up to 2,000 mcg per week; 250 mcg per day; 100 to 200 mcg | Weekly; daily; 2 to 3 times per day | Not stated | Regulator document describing vendor and clinic offers (Tier 6)[10] |
| Weight-based dosing outside trials | Both | Not applicable | Not applicable | None found; online figures are flat amounts | Not applicable | Not applicable | Conflicting reports: trials use mcg/kg, online pages do not convert[2][3][30] |
The aidsmap report puts enrollment at 192 completed; the registry record lists 120.[6][7] The Teichman abstract says “two or three weekly or biweekly doses,” meaning two or three doses spaced a week or two apart. The 2026 review table words it “2 to 3 times weekly or biweekly,” which is a looser reading.[2][18] The FDA briefing’s website figures do not say which form each belongs to.[10]
What “CJC-1295” means
Both forms start from the first 29 amino acids of the body’s own growth hormone releasing hormone (GHRH), the signal that tells the pituitary gland to release growth hormone. Four letters are swapped to make the chain last longer.[10] The “DAC” form then adds a small chemical hook, a maleimidopropionamide-lysine group, that locks onto the blood protein albumin and lets one injection last days.[1] The form without the hook is a different product.
The original paper that named CJC-1295 describes the hooked version: “a tetrasubstituted form of hGRF(1-29) with an added N epsilon-3-maleimidopropionamide derivative of lysine at the C terminus.”[1] So when a trial says CJC-1295, it means DAC. A wiki and a review both say the no-DAC chain is “Mod GRF 1-29” and that some sources wrongly treat the two as one.[9][18] That mix-up is the single biggest source of dosing confusion on the web.
Swipe the table sideways to see every column.
| Property | With DAC | Without DAC (Mod GRF 1-29) |
|---|---|---|
| Other names | CJC-1295 DAC, DAC:GRF in older press[8] | Modified GRF (1-29), Mod GRF, tetrasubstituted GRF (1-29) used loosely[9][18] |
| Chain | GHRH(1-29) with four substitutions (D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27), amidated end, plus the DAC group[10] | The same 29-residue chain without the DAC group[10] |
| Sequence written out | Not written out here | YaDAIFTQSYRKVLAQLSARKLLQDILSR-NH2 (a = D-Ala). Derived by me from the native sequence in DrugBank plus FDA’s four substitutions; FDA’s document is inconsistent on position 8 (Gln in one place, Glu in another).[10][28] |
| Formula, weight, CAS (free base, FDA table) | C165H269N47O46, 3647.95 g/mol, CAS 446262-90-4[10] | C152H252N44O42, 3367.95 g/mol, CAS 446036-97-1[10] |
| UNII | 62RC32V9N7, which FDA says maps to the DAC structure[10] | Not available in FDA’s table[10] |
| Half-life | About 5.8 to 8.1 days in healthy adults[2] | No human measurement found. Community pages say about 30 minutes, or 30 minutes to 2 hours (Tier 6).[30][34] |
| Human dosing studies | Yes: ascending-dose trials, a pulsatility study, a terminated Phase 2[2][3][6] | None in the peer-reviewed literature; a 2026 review places it in its lowest evidence tier[18] |
| Originator | ConjuChem Biotechnologies, Canada[9][10] | Not applicable; sold as a research chemical |
| PubChem CID and DrugBank ID | Not verified for this page | Not verified for this page |
Sermorelin is the same native 29-residue chain with no substitutions, which is why community pages compare the no-DAC form to it.[18]
Where these figures come from
The DAC numbers have a paper behind them, even if the online weekly amounts do not. The no-DAC numbers have nothing behind them except other websites.
- Most-reported DAC figure: 1 to 2 mg a week, with 2 mg once weekly the “most common” protocol on the wiki that tabulates it.[18][29][34]
- Most-reported no-DAC figure: 100 mcg per injection, with a range of 100 to 200 mcg, taken 2 to 3 times a day.[30][31][34]
- Origin of the DAC weekly figure: not found. The trials dosed per kilogram, and the most common online amount works out lower than the best-tolerated trial level for a 70 kg adult (my arithmetic, see the chart below).[2][29]
- Origin of the no-DAC figure: the wiki says it plainly. “No formal clinical dose-finding studies have been published specifically for the non-DAC form,” and its dosing is “derived from GHRH analog literature, saturation pharmacology reasoning, and commonly referenced research protocols.”[30] The one paper it cites is the DAC trial.
- The “saturation dose” idea: the claim that about 100 mcg (1 to 2 mcg/kg) fully occupies the receptor so more adds nothing. It appears on the wiki without a source, so it is a reasoning claim and not a measured result.[30]
- Websites repeating each other: the wiki, the database comparison page and the review list overlapping ranges. The wiki’s own source list is Reddit communities, dosing-calculator and guide sites, and clinic pages.[29][31] Agreement among them is not independent confirmation.
- Human evidence: DAC only, weight-based, single or a few doses, longest trial 49 days.[2]
- Disagreements: no-DAC frequency runs from once before bed to three times a day; DAC runs from 1 mg weekly to 2 mg twice a week to a 300 to 1,000 mcg twice-weekly climb.[29][31]
Detailed human data
Every human CJC-1295 study I found tested the long-acting DAC form in healthy adults or HIV patients, and none tested body composition, sleep, recovery or any of the goals the popular protocols aim at. The studies measured growth hormone (GH) and its liver-made partner IGF-1.
Swipe the table sideways to see every column.
| Study | Design and people | Amount | Main findings | Limits |
|---|---|---|---|---|
| Teichman 2006[2] | Two randomized, placebo-controlled, double-blind ascending-dose trials of 28 and 49 days in healthy adults aged 21 to 61, two sites | Four single doses, then 2 to 3 weekly or biweekly doses; 30 or 60 mcg/kg singled out | Single injection raised mean GH 2 to 10 times for 6 days or more and IGF-1 1.5 to 3 times for 9 to 11 days. Half-life 5.8 to 8.1 days. IGF-1 stayed above baseline up to 28 days after repeat doses. No serious adverse reactions. | Healthy volunteers, short, no body-composition outcome. All dose levels not in the abstract. |
| Ionescu and Frohman 2006[3] | Healthy men aged 20 to 40; GH sampled every 20 minutes over 12 overnight hours before and 1 week after one injection | 60 or 90 mcg/kg | GH pulses kept their frequency and size. Baseline (trough) GH rose 7.5 times, mean GH 46%, IGF-1 45%. No difference between the two doses. | Small, one injection, one week of follow-up. |
| Sackmann-Sala 2009[4] | 11 healthy young men, serum before and 1 week after one injection | Not stated in the abstract | Several serum proteins shifted, linked to GH and IGF-1 activity (apolipoprotein A1, transthyretin, beta-hemoglobin, albumin fragments). | A biomarker study, not an efficacy test. |
| Phase 2, HIV-associated visceral obesity (NCT00267527)[6][7] | Multicenter, randomized, placebo-controlled, double-blind; 12 weeks of treatment plus 6 weeks of follow-up planned; terminated | Low arm 60, 90, 120 mcg/kg; high arm 60, 120, 240 mcg/kg, once weekly (from a news report) | No results posted. The company stopped the study in July 2006 after a participant died. | Amounts come from trade press, not a paper or the registry. |
What the human data show
Four plain points. One injection of the DAC form kept growth hormone elevated for about a week and IGF-1 elevated for 9 to 11 days, which matches a half-life of roughly a week.[2] The natural on-off rhythm of GH pulses survived, but the floor between pulses rose 7.5 times, and the authors linked that rise to the IGF-1 increase.[3] Both effects were measured in healthy people over days or weeks. And the weekly online amounts sit below the per-kilogram levels the trials called best tolerated, if you spread 1 to 2 mg over a 70 kg adult (my arithmetic). A 2026 review reaches the same overall judgment: the DAC form has phase 1 data in healthy people but no controlled efficacy data.[18]
The Phase 2 trial and the death
ConjuChem tested the DAC form for HIV-associated visceral fat and stopped the study after a participant died. A trade report from July 2006 says the company halted the trial on July 17, that the participant attended a study site in Argentina, and that the cause and any link to the drug were under investigation.[7] A news service later reported that the company had posted its investigation findings, without stating them.[8] An encyclopedia entry says the attending physician considered coronary artery disease the likely cause, unrelated to treatment, and that research was ended as a precaution.[9] FDA’s briefing says only that ConjuChem withdrew the DAC form from trials in 2006 after the death, with no cause given.[10] I could not verify the cause from a primary document.
Animal research amounts
These numbers explain how the compound was characterized and what safety signals FDA weighed. They are not human doses, and I have not converted any of them. Rows from FDA’s briefing are as FDA summarized them, because I did not read the primary toxicology reports.
Swipe the table sideways to see every column.
| Research objective | Species or model | Amount | Frequency | Duration | Route | Source |
|---|---|---|---|---|---|---|
| Discovery and half-life | Sprague-Dawley rats | Single 1 µmol/kg (DAC TFA form); GH peak about 30 minutes, drug detectable up to 72 hours | Single dose | Acute | Subcutaneous | Jetté 2005; dose per FDA[1][10] |
| Growth normalization | GHRH-knockout mice, 1 week old | 2 mcg per mouse; daily dosing normalized weight and length, 48 and 72 hour intervals fell short | Every 24, 48 or 72 hours | 5 weeks | Subcutaneous, later intraperitoneal | Alba 2006[5][10] |
| Acute toxicity | Rats | 2, 4 or 8 mg/kg; food intake down 62 to 90% | Single dose | Acute | Intravenous | Summarized by FDA[10] |
| Acute toxicity | Beagle dogs | 2.5, 8, 24 or 40 mg/kg; reduced activity and vomiting at 8 mg/kg and up | Single dose | Acute | Subcutaneous | Summarized by FDA[10] |
| Repeat-dose toxicity | Rats | 0.25, 1 or 4 mg/kg; lower red cell counts, higher liver weight, injection-site effects | Every other day | 14 days | Intravenous | Summarized by FDA[10] |
| Repeat-dose toxicity | Beagle dogs | 40 mg/kg per day, or 0, 2, 6, 18 mg/kg per day; hemoglobin down about 16%, cholesterol up 1.8 times at 6 mg/kg per day and up | Daily | 7 or 14 days | Subcutaneous | Summarized by FDA[10] |
| Immune toxicity | Cynomolgus monkeys | 50 mcg/kg; no immunotoxic effect reported, FDA calls the data vague | Not stated | 6 months | Subcutaneous | Summarized by FDA[10] |
| Pituitary safety | Mice (C57BL/6) | 10 mcg/kg; pituitary DNA damage and higher pituitary weight | 3 times a week | 8 weeks | Subcutaneous | Ben-Shlomo 2020, summarized by FDA[10] |
Amounts range from micrograms per mouse to tens of milligrams per kilogram in dogs. No conversion to humans is attempted.
Practitioner and community-reported protocols
None of this is clinical evidence. It is what a person finds when they search, reported as each source states it, with the source type named. The wiki pages say outright that their protocols are anecdotal and unverified.[29][31]
Swipe the table sideways to see every column.
| Protocol or label | Form | Source type | Amount | Frequency and timing | Duration or cycle | Source |
|---|---|---|---|---|---|---|
| Weekly injection (“popular”) | DAC | Wiki, from “130 community reports” gathered from Reddit, calculator sites and clinic pages (Tier 6) | 2 mg | Once weekly | 12 to 16 weeks | [29] |
| Twice-weekly split (“common”) | DAC | Wiki (Tier 6) | 1 mg | Twice weekly | 12 to 16 weeks | [29] |
| Beginner titration (“common”) | DAC | Wiki (Tier 6) | 300 to 1,000 mcg, rising with tolerance | Twice weekly | 12 to 16 weeks | [29] |
| Low-dose anti-aging (“niche”) | DAC | Wiki (Tier 6) | 1 mg | Once weekly | Ongoing with breaks; some cycle 3 months on, 1 month off | [29] |
| Conservative, standard, split, loading | DAC | Database comparison page, no citations (Tier 6) | 1 mg; 2 mg; 1 mg; 2 mg then 1 mg | Weekly; weekly; Monday and Thursday; weekly | Not stated | [34] |
| Forum pattern | DAC | Peer-reviewed review tabulating forum reports (Tier 5 over Tier 6) | 1 to 2 mg per week | 1 to 2 injections | 8 to 12 or 12 to 16 weeks on, 4 to 6 weeks off | [18] |
| Physician guide with ipamorelin | DAC | Physician author, site tied to a telehealth practice (Tier 5) | About 2 mg, with 200 to 300 mcg ipamorelin | CJC weekly; ipamorelin nightly | 8 to 12 weeks then a 4 week break | [35] |
| Dosing page | No DAC | Wiki, no clinical citation for the dose (Tier 6) | 100 mcg per injection; “saturation” range 100 to 200 mcg | 2 to 3 times daily: before sleep, on waking, optionally mid-afternoon; at least 2 to 3 hours after a meal | 8 to 12 weeks, repeatable | [30] |
| Saturation dose with ipamorelin (“popular”) | No DAC | Wiki, from “180 community reports” (Tier 6) | 100 mcg with 100 mcg ipamorelin | 2 to 3 times daily | 8 to 16 weeks | [31] |
| Standard GHRH (“popular”) | No DAC | Wiki (Tier 6) | 100 to 200 mcg | 1 to 3 times daily | 8 to 12 weeks | [31] |
| Pre-bed only (“common”) | No DAC | Wiki (Tier 6) | 200 mcg with 200 mcg ipamorelin | Once daily before bed | 12 or more weeks, 5 days on and 2 off | [31] |
| Post-workout pulse (“niche”) | No DAC | Wiki (Tier 6) | 100 to 200 mcg | After training, 3 to 5 days a week | 8 to 12 weeks | [31] |
| Database ranges | No DAC | Database comparison page (Tier 6) | 100 to 300 mcg; 100 mcg; 100 to 150 mcg; 200 mcg with a GHRP; 100 to 200 mcg | 2 to 3 times daily; twice; 3 times; 2 to 3 times; once at bedtime | Not stated | [34] |
| Forum pattern | No DAC | Peer-reviewed review tabulating forum reports (Tier 5 over Tier 6) | 100 to 200 mcg per injection | 1 to 2 times daily, preferably after strength training | 12 to 16 weeks on, 4 to 6 weeks off | [18] |
| Individual blog post | No DAC | Individual author, no stated credentials (Tier 6) | No amount given | “5 nights a week, before bed” | Not stated | [36] |
Reconstitution as the wiki states it: with a 2 mg vial, adding 1 mL of bacteriostatic water gives 2 mg/mL (2,000 mcg/mL), a 100 mcg amount is 0.05 mL, which reads as 5 units on a 100-unit syringe. Storage per the same page: lyophilized powder at -20 C, mixed solution at 2 to 8 C and used within 14 to 21 days.[30] That is the source’s arithmetic for its own example, not a recommendation. The reconstitution calculator and reconstitution guide explain how to do the math for a concentration you set yourself.
FDA’s briefing adds what the sale side looks like: “research use” CJC-1295 without DAC offered as 2, 5 and 10 mg powders, DAC as 2 and 5 mg powders, and website recommendations from 100 mcg a week to 400 mcg a day, with one site capping at 2,000 mcg a week. It found one outsourcing facility reporting CJC-1295 with ipamorelin in 2019 and 2020, and none reporting CJC-1295 since 2020.[10]

CJC-1295 with ipamorelin: what is reported
“CJC-1295 ipamorelin” is the most-searched version of this topic. It is a community pairing of a GHRH analog with a ghrelin-receptor peptide, based on the idea that two different signals release more growth hormone than either alone. The ipamorelin half has its own page, ipamorelin dosage, and the product name is covered on the CJC-1295 and ipamorelin blend page.
Swipe the table sideways to see every column.
| Source | CJC-1295 form and amount | Ipamorelin amount | Frequency and timing | Duration | Evidence category |
|---|---|---|---|---|---|
| Wiki “saturation dose” protocol | No DAC, 100 mcg | 100 mcg | 2 to 3 times daily, combined | 8 to 16 weeks | Community, vendor or clinic reported (Tier 6)[31] |
| Wiki “pre-bed only” protocol | No DAC, 200 mcg | 200 mcg | Once before bed | 12 or more weeks, 5 on, 2 off | Community, vendor or clinic reported (Tier 6)[31] |
| Wiki ipamorelin page, stack protocol | No DAC, 100 to 200 mcg | 100 to 200 mcg | 2 to 3 times daily, combined injection | 8 to 16 weeks | Community, vendor or clinic reported (Tier 6)[32] |
| Physician guide, no-DAC stack | No DAC, 100 to 200 mcg | 200 to 300 mcg | Nightly, one injection, fasted, about 30 minutes before bed | 8 to 12 weeks, 4 week break; up to 6 months suggested by some | Practitioner reported (Tier 5)[35] |
| Physician guide, DAC stack | DAC, about 2 mg once weekly | 200 to 300 mcg nightly | Ipamorelin nightly, CJC weekly | Same cycle statement | Practitioner reported (Tier 5)[35] |
| Review of online practice | No DAC, 100 to 200 mcg | 200 to 300 mcg | CJC 1 to 2 times, ipamorelin 2 to 3 times a day | CJC 12 to 16 weeks, ipamorelin 8 to 12 weeks on | Practitioner reported (Tier 5), summarizing forums[18] |
| Wiki stack article | Not stated | 0.03 mg/kg twice daily for up to 7 days (ipamorelin ileus trial, cited from a review)[25] | Not stated for the pair | Not stated | States “no published randomized controlled trials have tested” the pair[33] |
| Outsourcing-facility report in FDA’s briefing | 6 mg/mL | 15 mg/mL | Multi-ingredient injection powder | 2019 to 2020 | Regulator document on a compounder’s report (Tier 6)[10] |
What exists on the pair, by evidence level
- Formally studied together: no controlled human trial of CJC-1295 with ipamorelin was found. Two guides from 2026, one reviewed by a physician, say the same.[33][37]
- Studied at class level: a growth hormone releasing hexapeptide plus GHRH acted synergistically in 18 men (1990), hexarelin 100 mcg plus GHRH(1-29) 100 mcg beat either alone in 7 healthy men and 10 men with type 1 diabetes (1996), and low-dose ghrelin plus GHRH was synergistic (2001). These were one-time intravenous provocation tests, not training protocols.[20][21][22]
- Mechanistically plausible: ipamorelin releases GH through a GHRP-like receptor and not the GHRH receptor, so the two signals can add.[23] No study tests that for these two peptides.
- Ipamorelin side: all human ipamorelin data are intravenous, from a 1999 single-dose study in healthy men and a 2014 Phase 2 trial after bowel surgery at 0.03 mg/kg twice daily for up to 7 days.[24][25]
- Animal mention: a 2026 sports-medicine review notes a mouse study of the pair with better muscle tension after steroid-induced loss. I could not locate the primary paper, so it is not used as evidence.[19]
- Practitioner and community reported: the tables above. One wiki says both peptides “may be drawn into the same syringe.” None of the sources I read cites stability or compatibility data for mixing them.[30]
- DAC with ipamorelin: reported by the physician guide and listed as a “common” stack on the DAC wiki page.[29][35] A once-weekly long-acting drug and a twice-daily short one do not follow the same logic as the popular no-DAC pairing, and no source tests it.
Escalation, timing, duration, routes
- Titration: the terminated Phase 2 stepped up over 3 weeks (60 to 90 to 120, or 60 to 120 to 240 mcg/kg), per a news report.[7] Online, the DAC “beginner titration” starts at 300 mcg twice weekly and rises with tolerance, and one database page lists a 2 mg first-week “loading” week.[29][34] No-DAC pages give fixed amounts.
- Timing: online sources say to inject before bed, on waking and sometimes mid-afternoon, fasted for 2 to 3 hours beforehand and about 30 minutes after.[30] The reasoning is that food blunts GH release. No source ties that advice to CJC-1295 measurements.
- Duration: the longest published exposure was 49 days of repeated doses.[2] The Phase 2 planned 12 weeks and was stopped.[6] Online cycles of 8 to 16 weeks with breaks have no study behind them.
- Why DAC and no-DAC schedules differ: DAC has a half-life of about a week and keeps a steady stimulus, with trough GH up 7.5 times and pulses preserved.[2][3] Community pages describe no-DAC as a short pulse of 30 minutes to 2 hours, which is why they inject it two or three times a day.[30][34] The half-life numbers for no-DAC come from the pages and not from a human measurement.
- Routes: subcutaneous in every human trial I found and in nearly every online protocol.[2][30] I found no human data for nasal, oral or other routes. The routes guide covers why route matters.
Side effects and quality risks
- Human trials: Teichman reported no serious adverse reactions and “relatively well tolerated” dosing, particularly at 30 or 60 mcg/kg.[2] A 2026 review adds that mild local and systemic effects related to GH axis stimulation were seen, and that long-term safety data do not exist.[18]
- FDA’s adverse event language: FDA’s withdrawn-nominations table says it “identified serious adverse events associated with CJC-1295 including increased heart rate and systemic” vasodilatory reaction, and that compounded CJC-1295 “may pose risk for immunogenicity for certain routes of administration.” The entry cites no reference.[12]
- The Phase 2 death: cause and link to the drug are not established in the sources I could read (see above).[7][9][10]
- Animal signals: in rats and dogs, lower red cell counts, higher liver weight and cholesterol, and injection-site effects at multi-milligram per kilogram amounts; in mice, pituitary DNA damage at 10 mcg/kg three times a week for 8 weeks. FDA cited genotoxicity signals for the DAC-related substances among its reasons.[10]
- Theoretical class concerns: sustained GH and IGF-1 stimulation raises mitogenic questions, with no established cancer signal and no long-term data.[18]
- Identity and purity: FDA found naming inconsistencies and one certificate of analysis listing a deleted CAS number for “CJC-1295 Acetate,” and the chemical-ID record for the no-DAC form is inconsistent.[10] A forensic lab found a modified GRF 1-29 with an extra glycine at one end in seized powders.[26] The COA reading guide covers what a certificate can and cannot prove. No seller is named on this page on purpose.
- Sport: CJC-1295 is listed under S2 of the WADA Prohibited List effective January 2026, with sermorelin and tesamorelin among GHRH analogs.[27]
Regulatory and development status
As of FDA pages read on 2 November 2026, CJC-1295 is not approved in any form and no label dose exists. ConjuChem withdrew the DAC form from clinical trials in 2006, and I found no later human trial.[6][10] The approved drug in this family is tesamorelin, a GHRH analog for HIV-associated lipodystrophy, which has its own entry.[19]
FDA lists: CJC-1295 appears on FDA’s table of bulk drug substances that were nominated for compounding and then withdrawn, with the safety wording quoted above. That table is not one of the three interim categories, so CJC-1295 has no category.[12] The 503A page, current as of 14 May 2026, explains that a pharmacy can compound only from a substance with a USP monograph, that is a component of an approved drug, or that is on the bulks list. The list in 21 CFR 216.23 names six substances, none a peptide.[13][15]
Advisory committee: on 4 December 2024 the Pharmacy Compounding Advisory Committee reviewed five forms for growth hormone deficiency: CJC-1295 free base, its acetate, and DAC as free base, acetate and trifluoroacetate. The committee voted on each form separately. Votes on inclusion were 0 yes to 13 no for free base, 1 yes to 12 no for acetate, and 0 yes to 13 no for each DAC form. FDA’s briefing concluded the criteria weighed against inclusion, citing incomplete characterization, unclear historical use, immunogenicity concerns with subcutaneous injection and genotoxicity signals for DAC-related substances.[10][11] The minutes record little discussion beyond one member’s comment on the lack of evidence of effectiveness for the free base.[11]
HHS policy: the interim enforcement-discretion policy published at the end of October 2026 covers six other peptides (BPC-157, TB-500, epitalon, Semax, KPV and MOTS-c), applies only to 503A pharmacies with a patient-specific prescription, and allows one listed ingredient per product, so a CJC-1295 and ipamorelin blend would fall outside it even if both were listed.[14][16] The July 2026 committee meeting did not put CJC-1295 on its agenda.[17] Our HHS policy post and the FDA peptide status page track the whole picture.
Products sold as research chemicals sit outside every category above. Labeling something “for research use” does not make it a compounded drug, an approved drug or a supplement.

What is not public
- Any human study of CJC-1295 without DAC. A 2026 review says none exists in the peer-reviewed literature.[18]
- The four single-dose levels and the multi-dose schedule of the Teichman trials beyond “30 or 60 mcg/kg.”[2]
- The route, results, cause of the participant death and full dosing of the terminated Phase 2.[6][7]
- The origin of the 1 to 2 mg weekly DAC pattern and of the 100 to 200 mcg two to three times daily no-DAC pattern.[18][30]
- Any controlled human trial of CJC-1295 with ipamorelin, and any stability data for mixing them.[33][37]
- Any human data on body composition, sleep, recovery or skin outcomes for either form.[18]
- A defensible conversion between the per-kilogram trial amounts and the flat online amounts. None exists in the sources read.
Frequently asked questions
What is the CJC-1295 dosage?
There is no approved or label dose. Published human work used only the long-acting DAC form, given under the skin at levels singled out as 30 or 60 mcg/kg, plus a single 60 or 90 mcg/kg injection in another study. Online protocols report 1 to 2 mg a week for DAC and 100 to 200 mcg two or three times daily for no-DAC, with no traced origin.[2][3][18][30]
What is the difference between CJC-1295 with DAC and without DAC?
DAC adds a chemical group that binds albumin and gives a half-life of about 5.8 to 8.1 days, so it is dosed weekly. Without DAC the chain is Mod GRF 1-29, which community pages describe as lasting 30 minutes to 2 hours. Only the DAC form was tested in published human studies.[1][2][18][30]
Is 100 mcg of CJC-1295 a studied dose?
No. A 100 mcg amount appears on wikis for the no-DAC form, and the wiki states that no formal dose-finding study exists for it. The trials used per-kilogram dosing of the DAC form.[2][3][30]
How often is CJC-1295 with DAC dosed?
Trials gave single doses or two to three doses spaced a week or two apart, and the terminated Phase 2 used weekly injections. Online protocols mostly say once weekly, or split into twice-weekly amounts.[2][7][29]
What is the CJC-1295 and ipamorelin dose?
Community pages report 100 to 200 mcg of each in one injection two to three times a day for 8 to 16 weeks, or 200 mcg of each before bed. A physician guide reports 200 to 300 mcg ipamorelin with 100 to 200 mcg CJC-1295 nightly. No controlled human trial of the pair was found. See the ipamorelin dosage page for the other half.[31][32][35][37]
How long is a CJC-1295 cycle?
Online sources report 8 to 16 weeks on, then 2 to 6 weeks off, with DAC cycles often 12 to 16 weeks. No study tested any cycle. The longest published exposure was 49 days.[2][18][29][30]
Is CJC-1295 dosed by body weight?
In trials, yes: mcg/kg of the DAC form. Online protocols use flat amounts, and no source supplies a conversion between the two.[2][3][30]
Is CJC-1295 FDA approved or legal to compound?
It is not approved. FDA lists it among withdrawn compounding nominations, an advisory committee voted against placing any of five forms on the 503A bulks list in December 2024, and it is not among the six peptides in HHS’s October 2026 enforcement-discretion policy.[11][12][14]
What side effects were reported, and what happened in the Phase 2 trial?
Healthy adults in the early trials had no serious adverse reactions. The Phase 2 in HIV-associated visceral obesity was stopped in 2006 after a participant died; the cause was not stated in the sources I could read. FDA cites reports of increased heart rate and a vasodilatory reaction, plus immunogenicity and genotoxicity concerns.[2][7][10][12]
Bottom line
CJC-1295 is interesting because one injection of the DAC form kept growth hormone and IGF-1 up for about a week while keeping the body’s pulse pattern. What is genuinely published: small trials in healthy adults at per-kilogram amounts of the DAC form, and a Phase 2 that ended with a death and no results.[2][3][6] What is merely reported online: 1 to 2 mg weekly for DAC and 100 to 200 mcg two or three times a day for the no-DAC form most people mean, with the pairing with ipamorelin layered on top and no human trial behind any of it.[18][30][31] What stays speculative: every body-composition, sleep and recovery claim. The practical trap is the name. A trial result for one molecule is routinely used to justify a dose of another. Regulatory status as of November 2026: not approved, no FDA category, voted down for the 503A list, and outside HHS’s six-peptide policy.[11][12][14]
Keep reading
Sources
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286. PMID 15817669. https://pubmed.ncbi.nlm.nih.gov/15817669/ Published animal research (Tier 3). Defines CJC-1295 as the DAC form.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PMID 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/ Published human clinical trial (Tier 1).
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702. PMID 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/ Published human clinical trial (Tier 1).
- Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. doi:10.1016/j.ghir.2009.03.001. PMID 19386527. https://pubmed.ncbi.nlm.nih.gov/19386527/ Published human study (Tier 1). Dose not stated in the abstract.
- Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006. PMID 16822960. https://pubmed.ncbi.nlm.nih.gov/16822960/ Published animal research (Tier 3).
- ClinicalTrials.gov. NCT00267527: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Evaluate the Efficacy and Safety of CJC 1295 Administered for 12 Weeks in HIV Infected Patients With HIV Associated Visceral Obesity. Sponsor: ConjuChem. Terminated; 120 enrolled; no results posted. https://clinicaltrials.gov/study/NCT00267527 Registered human trial (Tier 2).
- aidsmap. Lipodystrophy study halted after patient death. July 2006. https://www.aidsmap.com/news/jul-2006/lipodystrophy-study-halted-after-patient-death Trade-press report (Tier 5 or 6). Source of the Phase 2 dose arms.
- FDAnews. ConjuChem reveals findings of patient death investigation. 10 August 2006. https://fdanews.com/articles/print/61624-conjuchem-reveals-findings-of-patient-death-investigation Trade-press report. Does not state the findings.
- Wikipedia. CJC-1295 (encyclopedia entry citing ConjuChem 2006 reports). https://en.wikipedia.org/wiki/CJC-1295 Encyclopedia, secondary (Tier 6). Used only for naming and the attending physician’s view.
- U.S. Food and Drug Administration. CJC-1295: briefing document for the Pharmacy Compounding Advisory Committee, 4 December 2024. https://www.fda.gov/media/183819/download Regulator document. Text was truncated before the effectiveness section.
- U.S. Food and Drug Administration. Summary minutes, Pharmacy Compounding Advisory Committee, 4 December 2024 (CJC-1295, AOD-9604, thymosin alpha-1). https://www.fda.gov/media/185642/download Regulator document.
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 and withdrawn nominations tables). Content current as of 22 April 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks Regulator page.
- U.S. Food and Drug Administration. Bulk drug substances used in compounding under section 503A of the FDC Act. Content current as of 14 May 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act Regulator page.
- Office of the Secretary, HHS. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Docket HHS-OASH-2026-0496; Federal Register document 2026-22192 (public inspection copy, filed 28 October 2026). https://public-inspection.federalregister.gov/2026-22192.pdf Regulator document. The text read did not include Appendix A.
- Code of Federal Regulations. 21 CFR 216.23, bulk drug substances that can be used to compound drug products in accordance with section 503A (eCFR, current to 13 August 2026). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 Regulation.
- FDA Law Blog. The PEPTIDE-L wave reaches HHS: enforcement discretion, not the finish line. 28 October 2026. https://www.thefdalawblog.com/?p=16231 Law-firm commentary (Tier 5). Lists the six Appendix A peptides and the single-ingredient condition.
- U.S. Food and Drug Administration. July 23 and 24, 2026 meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 Regulator page. Agenda only; no minutes were posted when read.
- Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. 2026;17:1822475. doi:10.3389/fendo.2026.1822475. PMID 42395176. https://doi.org/10.3389/fendo.2026.1822475 Narrative review (Tier 5) that tabulates online self-administration patterns as behavioral data.
- Mayfield CK, Bolia IK, Feingold CL, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026;54(1):223-229. doi:10.1177/03635465251357593. PMID 41476424. https://pubmed.ncbi.nlm.nih.gov/41476424/ Narrative review (Tier 5).
- Bowers CY, Reynolds GA, Durham D, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982. doi:10.1210/jcem-70-4-975. PMID 2108187. https://pubmed.ncbi.nlm.nih.gov/2108187/ Published human clinical trial (Tier 1).
- Giustina A, Desenzani P, Perini P, et al. Hypothalamic control of growth hormone secretion in type I diabetic men: effect of the combined administration of GH-releasing hormone and hexarelin. Endocr Res. 1996;22(2):159-174. doi:10.1080/07435809609030505. PMID 8799695. https://pubmed.ncbi.nlm.nih.gov/8799695/ Published human clinical trial (Tier 1).
- Hataya Y, Akamizu T, Takaya K, et al. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J Clin Endocrinol Metab. 2001;86(9):4552. doi:10.1210/jcem.86.9.8002. PMID 11549707. https://pubmed.ncbi.nlm.nih.gov/11549707/ Published human clinical trial (Tier 1).
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PMID 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/ Published animal research (Tier 3) and laboratory research (Tier 4). Novo Nordisk authors.
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. doi:10.1023/a:1018955126402. PMID 10496658. https://pubmed.ncbi.nlm.nih.gov/10496658/ Published human clinical trial (Tier 1). Ipamorelin.
- Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. doi:10.1007/s00384-014-2030-8. PMID 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/ Published human clinical trial (Tier 1). Ipamorelin.
- Gajda PM, Holm NB, Hoej LJ, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Test Anal. 2018;11(2):350-354. doi:10.1002/dta.2489. PMID 30136411. https://pubmed.ncbi.nlm.nih.gov/30136411/ Laboratory analysis of seized material (Tier 4).
- German Sport University Cologne, Department of Biochemistry. S2 peptide hormones, growth factors, related substances and mimetics (reflects the WADA list effective 1 January 2026). https://www.dshs-koeln.de/en/universitaet/organisation/institute-einrichtungen/department-of-biochemistry/doping-substances/prohibited-classes-of-substances-and-methods/s2-peptide-hormones-growth-factors-etc Anti-doping laboratory page quoting the WADA list.
- DrugBank. Sermorelin (DB00010), native GHRH(1-29) sequence record. https://www.drugbank.ca/r/DB00010 Drug database. Lists 30 residues in one field despite describing a 29-residue peptide.
- Peptide Protocol Wiki Team. CJC-1295 DAC: community protocols and reports. https://www.peptideprotocolwiki.com/peptides/cjc-1295-dac/community Community, vendor or clinic reported (Tier 6). States the reports are anecdotal.
- Peptide Protocol Wiki Team. CJC-1295 without DAC (Modified GRF 1-29): dosing. https://www.peptideprotocolwiki.com/peptides/cjc-1295-no-dac/dosing Community, vendor or clinic reported (Tier 6). Page admits no non-DAC dose-finding study exists.
- Peptide Protocol Wiki Team. CJC-1295 without DAC: community protocols and reports. https://www.peptideprotocolwiki.com/peptides/cjc-1295-no-dac/community Community, vendor or clinic reported (Tier 6). States the reports are anecdotal.
- Peptide Protocol Wiki Team. Ipamorelin: community protocols and reports. https://www.peptideprotocolwiki.com/peptides/ipamorelin/community Community, vendor or clinic reported (Tier 6).
- Peptide Protocol Wiki Team. CJC-1295 and ipamorelin stack: growth hormone secretagogue research guide. 8 February 2026. https://www.peptideprotocolwiki.com/blog/cjc-1295-ipamorelin-stack Community, vendor or clinic reported (Tier 6). Gives no stack dose of its own.
- Peptide Database. CJC-1295 (without DAC) vs CJC-1295 with DAC: complete comparison. https://peptide-db.com/compare/cjc-1295-vs-cjc-1295-dac Community, vendor or clinic reported (Tier 6). Lists study counts but no citations.
- Physician-authored ipamorelin and CJC-1295 stack guide on a site that refers readers to a telehealth practice (site not named on purpose; address held by the editor). Practitioner reported (Tier 5). Dosing figures carry no citation.
- Individual Substack author “GLP-1 Real Talk.” Peptide Tuesday: my full stack. 15 July 2025. https://glp1realtalk.substack.com/p/peptide-tuesday-my-full-stack-what Community, vendor or clinic reported (Tier 6). No amounts given.
- Superpower. CJC-1295 and ipamorelin: a GHRH-plus-ghrelin-mimetic combination (guide reviewed by a physician). Published 18 April 2026. https://superpower.com/guides/cjc-1295-ipamorelin-stack Commercial health-testing company guide (Tier 5 or 6). Says no controlled human trial of the pair exists as of September 2026.
Educational reference only, not medical advice. This page documents amounts in published and registered research, regulator documents and figures circulating online. It does not tell any reader what to take, and it does not say any amount is safe or effective. Talk to a qualified, licensed clinician about personal medical decisions.